1. Refers to percent of lives covered at parity or better to biosimilar(s) taking into account new and existing patients nationally.
2. Refers to Medicare Part B coverage.
3. Check mark indicates product covered by payer at parity or better to biosimilar(s) versus a biosimilar, where there is a biosimilar commercially available.
Insurer/payer policies are subject to change. The completion and submission of coverage or reimbursement-related documentation are the responsibility of the patient and the healthcare provider. Genentech makes no guarantee concerning coverage or reimbursement for any service or item. Inclusion of a plan or product is not intended to imply a recommendation of a particular plan or product. Coverage percentage shown is a weighted average based on national patients treated for Avastin, Herceptin, and Rituxan.
References: Data on file. Genentech Inc. MMIT Analysis. IQVIA Plantrak Corticosteroid Data. HLI lives database.
Genentech USA, Inc.
1 DNA Way
South San Francisco, CA
This email was sent to firstname.lastname@example.org because you have an account with or are a valued partner of ION Solutions. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.